Edema Clinical Trials Market Revenue Expected to Reach $1.7 Billion by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 How Has the Edema Clinical Trials Market Performed Historically, and What Are Its Future Growth Projections?
 The edema clinical trials market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of edema conditions, rising burden of chronic diseases, growing healthcare awareness and diagnosis, surge in healthcare infrastructure expansion, increasing geriatric population, and rising public and private funding.
 
 The edema clinical trials market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growing demand for personalized medicine, rising emphasis on patient recruitment diversity, surge in decentralized and virtual clinical trials, expansion of government support programs, and rising investment from global pharmaceutical companies. Major trends in the forecast period include technological advancements in remote monitoring, innovation in digital biomarkers, development of artificial intelligence analytics, advancements in three dimensional imaging, research and development in personalized therapies, and integration of telemedicine in trials.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28211&type=smp
 
 What Are the Major Growth Drivers for the Edema Clinical Trials Market?
 The increasing incidence of lifestyle-related diseases is expected to propel the growth of the edema clinical trials market going forward. Lifestyle-related diseases are illnesses that arise from daily behaviors and choices, including sedentary lifestyle, unhealthy eating, and substance use. Lifestyle-related diseases are increasing due to unhealthy dietary habits, as the widespread consumption of processed and high-calorie foods contributes to obesity, diabetes, and cardiovascular problems. Edema clinical trials support lifestyle-related diseases by developing and assessing treatments that address fluid buildup linked to obesity, diabetes, and cardiovascular conditions. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing incidence of lifestyle-related diseases is driving the growth of the edema clinical trials market.
 
 What Are the Major Segments Defining the Structure of the Edema Clinical Trials Market?
 The edema clinical trials market covered in this report is segmented as
 
 1) By Phase: Phase I, Phase II, Phase III, Phase IV
 2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema
 3) By Study Design: Interventional, Observational, Expanded Access
 4) By Participant: Pediatrics, Adults, Geriatrics
 5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers
 
 Subsegments:
 1) By Phase I: Single Ascending Dose, Multiple Ascending Dose
 2) By Phase II: Proof of Concept, Phase IIb Dose Optimization
 3) By Phase III: Pivotal Efficacy Trials, Comparative Trials
 4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies
 
 Which Emerging Trends Are Shaping the Future of the Edema Clinical Trials Market?
 Major companies operating in the edema clinical trials market are focusing on developing innovative solutions such as refillable ocular implants to improve treatment efficacy and patient compliance in managing chronic edema-related eye conditions. A refillable ocular implant refers to a medical device implanted in the eye that can continuously deliver medication over an extended period and allows periodic refilling of the drug without needing to remove or replace the implant, ensuring sustained treatment for chronic eye conditions like macular edema. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, received approval from the FDA for Susvimo as the first and only continuous delivery treatment for diabetic macular edema (DME) and diabetic retinopathy (DR), both major causes of diabetes-related blindness, offering an alternative to frequent eye injections with significantly fewer annual treatments. This innovative approval marks a significant advancement in ophthalmic care, as Susvimo’s implantable delivery system helps improve patient compliance and reduces the treatment burden, potentially enhancing long-term outcomes for individuals living with these chronic eye conditions.
 
 Which Companies Hold a Prominent Position in the Edema Clinical Trials Market?
 Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.
 
 Get the detailed edema clinical trials market report today
 https://www.thebusinessresearchcompany.com/report/edema-clinical-trials-global-market-report
 
 What Are the Fastest-Growing Regions in the Edema Clinical Trials Market?
 North America was the largest region in the edema clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in edema clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company